V 
Vertex Pharmaceuticals VRTX · USD
Health Care · Biotechnology · US listing · 🇺🇸 United States
S&P 500Nasdaq-100
550.87
+0.69%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$12.07bn
FY2016FY2025
Net income
$3.95bn
FY2016FY2025
Free cash flow
$3.19bn
FY2016FY2025
Shareholders' equity
$18.67bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.07bn | $11.02bn | $9.87bn | $8.93bn | $7.57bn | $6.21bn | $4.16bn | $3.05bn | $2.49bn | $1.70bn |
| Gross profit | $10.27bn | $9.49bn | $8.61bn | $7.85bn | $6.67bn | $5.47bn | $3.62bn | $2.64bn | $2.21bn | $1.49bn |
| Research and development | $3.75bn | $3.63bn | $3.16bn | $2.66bn | $3.05bn | $1.83bn | $1.75bn | $1.42bn | $1.32bn | $1.05bn |
| Operating income | $4.76bn | −$232.9m | $3.83bn | $4.31bn | $2.78bn | $2.89bn | $1.20bn | $635.1m | $123.2m | $9.9m |
| Net income | $3.95bn | −$535.6m | $3.62bn | $3.32bn | $2.34bn | $2.71bn | $1.18bn | $2.10bn | $263.5m | −$112.1m |
| Diluted earnings per share | 15.44 | -2.06 | 13.87 | 12.76 | 9.11 | 10.31 | 4.49 | 8.07 | 1.03 | -0.45 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $26.14bn | $22.53bn | $22.73bn | $18.15bn | $13.43bn | $11.75bn | $8.32bn | $6.25bn | $3.55bn | $2.89bn |
| Cash and short-term investments | $6.61bn | $6.12bn | $11.22bn | $10.78bn | $7.52bn | $6.66bn | $3.81bn | $3.17bn | $2.09bn | $1.43bn |
| Total liabilities | $7.48bn | $6.12bn | $5.15bn | $4.24bn | $3.33bn | $3.06bn | $2.23bn | $1.81bn | $1.50bn | $1.56bn |
| Debt | $82.8m | $118.0m | $426.7m | $471.6m | $556.7m | $581.5m | $568.9m | $591.4m | $606.4m | $840.8m |
| Shareholders' equity | $18.67bn | $16.41bn | $17.58bn | $13.91bn | $10.10bn | $8.69bn | $6.09bn | $4.44bn | $2.04bn | $1.34bn |
| Shares outstanding | 256m | 261m | 261m | 260m | 257m | 263m | 262m | 260m | 257m | 248m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $3.63bn | −$492.6m | $3.54bn | $4.13bn | $2.64bn | $3.25bn | $1.57bn | $1.27bn | $844.9m | $236.1m |
| Capital spending | −$437.6m | −$297.7m | −$258.4m | −$204.7m | −$235.0m | −$259.8m | −$75.5m | −$95.5m | −$259.4m | −$56.6m |
| Free cash flow | $3.19bn | −$790.3m | $3.28bn | $3.93bn | $2.41bn | $2.99bn | $1.49bn | $1.17bn | $585.5m | $179.5m |
| Dividends paid | — | — | — | — | −$102.0m | −$264.9m | −$10.0m | −$20.8m | — | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.33bn | $2.99bn | $3.23bn | $3.08bn | $2.96bn | $2.77bn | $2.91bn | $2.77bn |
| Gross profit | $2.84bn | $2.59bn | $2.76bn | $2.66bn | $2.56bn | $2.41bn | $2.49bn | $2.38bn |
| Operating income | $1.25bn | $1.14bn | $1.30bn | $1.19bn | $1.15bn | $630.1m | $1.03bn | $1.12bn |
| Net income | $1.10bn | $1.03bn | $1.19bn | $1.08bn | $1.03bn | $646.3m | $913.0m | $1.05bn |
| Diluted earnings per share | 4.30 | 4.03 | 4.65 | 4.23 | 4.03 | 2.52 | 3.50 | 4.01 |
| Cash from operations | $1.13bn | $1.43bn | $498.0m | $1.24bn | $1.07bn | $818.0m | $584.0m | $1.37bn |
| Capital spending | −$112.0m | −$133.0m | −$149.0m | −$101.0m | −$145.0m | −$40.0m | −$92.0m | −$67.0m |
| Free cash flow | $1.01bn | $1.29bn | $349.0m | $1.14bn | $928.0m | $778.0m | $492.0m | $1.30bn |
| Total assets | $27.42bn | $26.48bn | $26.14bn | $24.86bn | $24.04bn | $22.88bn | $22.53bn | $22.24bn |
| Cash and short-term investments | $7.85bn | $7.25bn | $6.61bn | $6.29bn | $6.38bn | $6.20bn | $6.12bn | $6.52bn |
| Debt | — | — | $82.8m | — | — | — | $92.3m | −$220.0m |
| Shareholders' equity | $20.25bn | $19.36bn | $18.67bn | $17.32bn | $17.18bn | $16.50bn | $16.41bn | $15.63bn |
Financial ratios
Data as of 8 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 85.0% | 86.1% | 87.2% | 87.9% | 88.1% | 88.1% |
| Operating margin | 39.4% | -2.1% | 38.8% | 48.2% | 36.7% | 46.6% |
| Net margin | 32.7% | -4.9% | 36.7% | 37.2% | 30.9% | 43.7% |
| Return on equity | 21.2% | -3.3% | 20.6% | 23.9% | 23.2% | 31.2% |
| Return on assets | 15.1% | -2.4% | 15.9% | 18.3% | 17.4% | 23.1% |
| Free cash flow yield | 2.9% | -0.1% | 2.7% | 3.0% | 2.1% | 2.4% |
| Revenue growth | 9.6% | 11.7% | 10.5% | 17.9% | 22.1% | 49.1% |
| Earnings growth | -838.1% | -114.8% | 9.0% | 41.8% | -13.6% | 130.4% |
| Current ratio | 2.90x | 2.69x | 3.99x | 4.83x | 4.46x | 4.33x |
| Debt to equity | 0.00x | 0.01x | 0.00x | 0.01x | 0.01x | 0.00x |
| Equity ratio | 71.4% | 72.8% | 77.3% | 76.7% | 75.2% | 73.9% |
| Interest coverage | 357.95x | -7.61x | 86.89x | 78.60x | 45.24x | 49.74x |
| R&D as a share of sales | 31.1% | 32.9% | 32.0% | 29.7% | 40.3% | 29.5% |
| Buybacks as a share of market value | 1.7% | 0.2% | -0.2% | -1.3% | 2.3% | -0.4% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 10.6% | 14.2% | 27.9% |
| Operating income | 3.4% | 10.5% | — |
| Net income | 6.0% | 7.8% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 85.5% | 86.4% | 86.9% | 86.9% |
| Operating margin | 19.6% | 30.2% | 32.9% | 29.1% |
| Net margin | 14.8% | 24.7% | 27.7% | 26.8% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 29.4 | -195.9 | 29.3 | 22.6 | 24.1 | 22.9 | 48.8 | 20.5 | 146.1 | -162.9 |
| Price to sales | 9.6 | 9.5 | 10.8 | 8.4 | 7.5 | 10.0 | 13.8 | 14.1 | 15.5 | 10.7 |
Market value over time
31 Oct 2016 to 4 Sept 2026, in USD
$18.59bn$139.64bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | -0% | 11% | 38% | 35% | -8% | 6% | 37% | 11% | 90% | -38% |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years.
- 2-for-1 split · 24 Aug 2000
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.